Oxygenta Pharmaceutical Limite
BSE: OXYGENTAPH · Pharmaceuticals · sector
₹48.00BSE close 2026-10-26
Key numbers
Market cap₹178 cr
Price₹48.00
52w high / low₹72 / ₹43
P/E13.1xSector median 27.9x
P/B–Sector median 2.9x
Book value₹-11.5
Dividend yield–Sector median 0.48%
ROE–Sector median 11.7%
ROCE-14.9%Sector median 12.3%
OPM-5.9%Sector median 14.0%
Debt / equity–Sector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-1.5x
Current ratio0.60x
Sales growth 3y+53.9%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2 cr vs borrowings ₹110 cr (FY26): borrowings are higher by ₹107 cr.
- Operating profit covered interest -1.5x in the last 12 months.
- Net loss in 6 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹48.00 on 2026-10-26: -33.0% from the 52-week high, +11.6% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹121.73 · low ₹46.75
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 49 | 15 | 14 | 34 | 50 | 37 |
| EBITDA | -2 | -7 | -5 | -4 | 0 | 1 |
| OPM % | -3.9% | -45.2% | -32.0% | -12.0% | 0.2% | 1.5% |
| Other income | 0 | 0 | -0 | 0 | 0 | 0 |
| Net profit | -2 | -6 | -5 | -5 | -2 | -2 |
| EPS (₹) | 0.60 | 1.65 | 1.33 | 1.32 | 0.45 | 0.57 |
| Revenue YoY | +0.3% | +144.5% | ||||
| Profit YoY | – | – |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 61 | 31 | 40 | 109 | 113 | 135 |
| EBITDA | 2 | -8 | -10 | -10 | -15 | -8 |
| Net profit | -1 | -12 | -3 | -10 | -18 | -14 |
| EPS (₹) | -0.48 | -6.36 | -1.09 | 2.86 | 4.75 | 3.67 |
| Revenue growth | -48.8% | +27.9% | +175.7% | +3.4% | – | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +53.9% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -31.6% (2y) | -23.4% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | -26 | -43 |
| Borrowings | 62 | 110 |
| Cash & equivalents | 0 | 2 |
| Total assets | 83 | 120 |
| Fixed assets | 37 | 48 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Receivables | 5 | 10 |
| Inventory | 21 | 29 |
| Payables | 30 | 49 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 3 | -28 |
| Cash from investing | -11 | -14 |
| Cash from financing | 9 | 43 |
| Capex | 11 | 13 |
| Free cash flow | -9 | -41 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 40.2% | 41.2% |
| ROCE % | -29.3% | -26.0% |
| Debtor days | 17 | 32 |
| Inventory days | 78 | 105 |
| Payable days | 113 | 174 |
| Cash conversion cycle (days) | -18 | -37 |
| Working capital days | -183 | -112 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| OXYGENTAPH | ₹178 cr | 13.1x | – | – | -14.9% | -5.9% | +53.9% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | OXYGENTAPH |
| BSE code | 524636 |
| ISIN | INE102E01018 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.